Results 51 to 60 of about 205,670 (312)

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial [PDF]

open access: yesJournal of Immunotherapy and Precision Oncology
Introduction TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and have demonstrated efficacy
Mirella Nardo   +19 more
doaj   +1 more source

Pocket Book for Simulation Debriefing in Healthcare [PDF]

open access: yes, 2017
© 2018 Springer International Publishing AG. This is a post-peer-review, pre-copyedit sample portion of 'Pocket Book for Simulation Debriefing in Healthcare'.
Alinier, Guillaume, Oriot, Denis
core   +2 more sources

Immune‐Driven Expression in Inclusion Body Myositis With T‐Cell Large Granular Lymphocytic Leukemia

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives T‐cell large granular lymphocytic leukemia (T‐LGLL), reported in up to 58% of inclusion body myositis (IBM) patients, is a rare leukemia of cytotoxic or less commonly helper T cells. The range of myopathies in T‐LGLL and the impact of coexisting T‐LGLL in IBM are not well understood. Our objectives are to investigate the spectrum of
Pannathat Soontrapa   +10 more
wiley   +1 more source

Stem cell clinical trials [PDF]

open access: yes, 2013
No description ...
Rosemann, Achim
core  

New Phosphated Poly(methyl Methacrylate) Polymers for the Prevention of Denture-induced Microbial Infection: an In Vitro Study [PDF]

open access: yes, 2011
Purpose: Poly(methyl methacrylate) (PMMA) has been widely used as a denture-base acrylic resin due to its excellent physical and mechanical properties.
Dentino, Andrew R., Raj, Antony
core   +3 more sources

A Prospective Study of Individuals at Risk of Multiple Sclerosis Informs the Design of Primary Prevention Studies

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen   +7 more
wiley   +1 more source

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

open access: yesnpj Precision Oncology, 2023
Pre-clinically, the mTORC1/2 inhibitor sapanisertib restored sensitivity to platinums and enhanced paclitaxel-induced cancer cell killing. NCT03430882 enrolled patients with mTOR pathway aberrant tumors to receive sapanisertib, carboplatin and paclitaxel.
Omar Alhalabi   +20 more
doaj   +1 more source

A Research Documentation On Men's Sexual Health Disclosed [PDF]

open access: yes, 2010
When VigRX Plus was surveyed by Vedic Life-Sciences in proved to be the best pill treatment for sexual health.

core  

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients With Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

open access: yesArthritis Care &Research, EarlyView.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; ClinicalTrials.gov identifier ...
Hermine I. Brunner   +14 more
wiley   +1 more source

Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD Anderson

open access: yesnpj Precision Oncology
We evaluated clinical outcomes and safety profiles in patients with non-small cell lung cancer (NSCLC) treated in early-phase trials. A retrospective review of 546 NSCLC cases treated from January 2016 to December 2024 at The University of Texas MD ...
Jeong Uk Lim   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy